Finance

Lists
Why is SPTX up 3.22%?
Dive Deeper
SPTX:NASDAQ
Seaport Therapeutics Inc
$17.93
+3.22%
(+0.56) 1D
$17.93
0.00% (0.00)
After hours
Closed: Oct 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SPTX...
Open
$17.28
High
$18.29
Low
$17.07
Mkt. cap
959.80M
Avg. vol.
256.60K
Volume
249.08K
52-wk high
$28.38
52-wk low
$14.85
No. of employees
58
Open
$17.28
High
$18.29
Low
$17.07
Mkt. cap
959.80M
Avg. vol.
256.60K
Volume
249.08K
52-wk high
$28.38
52-wk low
$14.85
No. of employees
58
News stories
From web sources and news partners
About Seaport Therapeutics Inc
CEODaphne Zohar
Employees58
Founded2024
HeadquartersBoston, Massachusetts, United States
SectorPharmaceutical industry
Websiteseaporttx.com
Analyst ratings
Based on 5 analysts giving stock ratings to SPTX in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for SPTX in the last 3 months.
Highest
Current $17.93
$50.00 (+178.86%)
Average
$38.60 (+115.28%)
Lowest
$30.00 (+67.32%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tiago Fauth
Raymond James
Buy
Initiated
$46.00
+156.6%
09/25/2026
Justin Walsh
JonesTrading
Buy
Reiterated
$32.00
+78.5%
09/10/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$35.00
+95.2%
09/10/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$50.00
+178.9%
09/10/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$30.00
+67.3%
08/13/2026
Rudy Li
Wolfe Research
Hold
Initiated
-
-
07/07/2026
Tessa Romero
J.P. Morgan
Buy
Reiterated
$42.00
+134.2%
06/08/2026
Marc Goodman
Leerink Partners
Buy
Initiated
$35.00
+95.2%
05/27/2026
Last report
Aug 3, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.78 / -$0.66
-171.19%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.53M
12.80M
20.86M
24.38M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.65M
5.06M
6.11M
41.19M
Operating expense
16.18M
17.86M
26.98M
65.57M
Total operating expenses
16.18M
17.86M
26.98M
65.57M
Operating income
-16.18M
-17.86M
-26.98M
-65.57M
Other non operating income
-9.00K
-59.00K
-46.00K
-34.00K
EBT including unusual items
-13.09M
-14.94M
-24.89M
-62.35M
EBT excluding unusual items
-13.09M
-14.94M
-24.89M
-62.35M
Income tax expense
31.00K
134.00K
519.00K
251.00K
Effective tax rate
-0.24%
-0.90%
-2.09%
-0.40%
Other operating expenses
-
-
-
-
Net income
-13.12M
-15.08M
-25.41M
-62.60M
Net profit margin
-
-
-
-
Earnings per share
-
-
-10.34
-1.78
Interest and investment income
3.10M
2.98M
2.13M
3.26M
Interest expense
-
-
-
-
Net interest expenses
3.10M
2.98M
2.13M
3.26M
Depreciation and amortization charges
-
-
-
-
EBITDA
-16.15M
-17.82M
-26.95M
-65.55M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps